MedTrace Logo

Improvements in Cognitive Skills of Older Adults Using Dynamic Visual Attention Training

NCT03456986 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-03-04

No results posted yet for this study

Summary

The proposed SBIR Phase I study tests the feasibility of PATH neurotraining for improving cognitive skills in older adults and, potentially, forestalling or protecting against cognitive decline and dementia. The feasibility of PATH neurotraining will be evaluated by comparing it with another cognitive training program, Brain HQ's Target Tracker, and ascertaining the relative advantage(s) of PATH neurotraining for enhancing cognition in older adults between 55 and 75 years of age whose cognition is either in the age-normative range or in the mild cognitive impairment (MCI) range of standardized psychometric measures. MEG/MRI source imaging will be used on 12 of the PATH group participants to determine whether the behavioral results are verified by improvements in the dorsal, attention, and executive control networks.

Conditions

  • Age Related Cognitive Decline

Interventions

BEHAVIORAL

PATH neurotraining

Tunes up the center of the motion discrimination (dorsal stream) working range

BEHAVIORAL

Orientation Discrimination

Tunes up the ventral stream most sensitive to high contrast and colored patterns.

Sponsors & Collaborators

Principal Investigators

  • Teri Lawton, PhD · Perception Dynamics Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-04
Primary Completion
2019-04-30
Completion
2021-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03456986 on ClinicalTrials.gov